ImmuPharma plc (LON:IMM – Get Free Report) traded up 12.5% during trading on Thursday . The company traded as high as GBX 5.80 ($0.07) and last traded at GBX 5.50 ($0.07). 19,527,068 shares were traded during mid-day trading, a decline of 23% from the average session volume of 25,520,734 shares. The stock had previously closed at GBX 4.89 ($0.06).
ImmuPharma Stock Performance
The firm has a market capitalization of £22.90 million, a P/E ratio of -550.00 and a beta of 1.53. The firm has a 50 day simple moving average of GBX 1.98 and a two-hundred day simple moving average of GBX 1.80.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- How to Effectively Use the MarketBeat Ratings Screener
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- 3 Healthcare Dividend Stocks to Buy
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
